NCT04313647View on ClinicalTrials.gov

A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

July 31, 2020

Conditions
Healthy
Interventions
BIOLOGICAL

1X level of MSCs-Exo

Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)

BIOLOGICAL

2X level of MSCs-Exo

Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)

BIOLOGICAL

4X level of MSCs-Exo

Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)

BIOLOGICAL

6X level of MSCs-Exo

Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)

BIOLOGICAL

8X level of MSCs-Exo

Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)

Trial Locations (1)

200025

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Ruijin Hospital

OTHER

NCT04313647 - A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers | Biotech Hunter | Biotech Hunter